Cambridge, MA, United States of America

Guangyan Du

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Blueprint Medicines Corporation. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guangyan Du. Retrieved from https://idiyas.com/inventor/guangyan-du-2uuagtpw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Guangyan Du: Innovator in Pharmaceutical Development

Introduction

Guangyan Du is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases. His work is instrumental in advancing treatments for various disorders and diseases.

Latest Patents

Guangyan Du holds a patent for a compound represented by Formula (I), which is useful for inhibiting wild type c-kit kinase. This compound, or its pharmaceutically acceptable salt, is designed to treat disorders mediated by wild type c-kit kinase in both humans and non-humans. His innovative approach has the potential to impact therapeutic strategies significantly.

Career Highlights

Du is currently associated with Blueprint Medicines Corporation, where he continues to push the boundaries of pharmaceutical research. His expertise in kinase inhibitors has positioned him as a key player in the development of targeted therapies.

Collaborations

Some of his notable coworkers include Jason D Brubaker and Yinghui Dai, who collaborate with him on various projects within the company.

Conclusion

Guangyan Du's contributions to the field of pharmaceuticals, particularly through his patent on wild type kit inhibitors, highlight his role as an innovator in the industry. His work at Blueprint Medicines Corporation continues to pave the way for advancements in treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…